SLU7 and acute myeloid leukemia: However, a phase 2 trial of 12 patients evaluating E7820 in splicing factor mutant AML, MDS, or CMML did not meet its primary endpoint of >1 patient achieving an objective response (Bewersdorf et al., 2023a).